Browse SRSF10

Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus speckle Cytoplasm
Domain PF00076 RNA recognition motif. (a.k.a. RRM
Function

Splicing factor that in its dephosphorylated form acts as a general repressor of pre-mRNA splicing (PubMed:11684676, PubMed:12419250, PubMed:14765198). Seems to interfere with the U1 snRNP 5'-splice recognition of SNRNP70 (PubMed:14765198). Required for splicing repression in M-phase cells and after heat shock (PubMed:14765198). Also acts as a splicing factor that specifically promotes exon skipping during alternative splicing (PubMed:26876937). Interaction with YTHDC1, a RNA-binding protein that recognizes and binds N6-methyladenosine (m6A)-containing RNAs, prevents SRSF10 from binding to its mRNA-binding sites close to m6A-containing regions, leading to inhibit exon skipping during alternative splicing (PubMed:26876937). May be involved in regulation of alternative splicing in neurons, with isoform 1 acting as a positive and isoform 3 as a negative regulator (PubMed:12419250).

> Gene Ontology
 
Biological Process GO:0000244 spliceosomal tri-snRNP complex assembly
GO:0000245 spliceosomal complex assembly
GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000387 spliceosomal snRNP assembly
GO:0000398 mRNA splicing, via spliceosome
GO:0006376 mRNA splice site selection
GO:0006397 mRNA processing
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0008380 RNA splicing
GO:0015931 nucleobase-containing compound transport
GO:0016482 cytosolic transport
GO:0022613 ribonucleoprotein complex biogenesis
GO:0022618 ribonucleoprotein complex assembly
GO:0033119 negative regulation of RNA splicing
GO:0043484 regulation of RNA splicing
GO:0048024 regulation of mRNA splicing, via spliceosome
GO:0048025 negative regulation of mRNA splicing, via spliceosome
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0050684 regulation of mRNA processing
GO:0050686 negative regulation of mRNA processing
GO:0051028 mRNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
GO:0071826 ribonucleoprotein complex subunit organization
GO:1903311 regulation of mRNA metabolic process
GO:1903312 negative regulation of mRNA metabolic process
Molecular Function GO:0050733 RS domain binding
GO:0051082 unfolded protein binding
Cellular Component GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0030424 axon
GO:0030425 dendrite
GO:0033267 axon part
GO:0043025 neuronal cell body
GO:0043679 axon terminus
GO:0044297 cell body
GO:0044306 neuron projection terminus
> KEGG and Reactome Pathway
 
KEGG hsa03040 Spliceosome
Reactome R-HSA-74160: Gene Expression
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRSF10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SRSF10 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29429992Cervical CarcinomaInhibit immunitySRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. SRSF10-mediated mIL1RAP upregulates the expression of the "don't eat me" signal CD47 to inhibit macrophage phagocytosis by promoting nuclear factor-κB activation, which is pivotal in inflammatory, immune, and tumorigenesis processes.
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRSF10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRSF10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.140.572
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0560.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2790.794
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0030.993
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0630.978
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0810.978
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0510.911
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1010.963
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.040.987
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0390.98
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7480.75
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0850.0826
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRSF10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRSF10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRSF10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRSF10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRSF10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRSF10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRSF10
Nameserine/arginine-rich splicing factor 10
Aliases TASR1; TASR2; SRp38; SRrp40; SFRS13; PPP1R149; splicing factor, arginine/serine-rich 13; SR splicing factor ......
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRSF10 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.